Oxidative stress, inflammation, and vascular function in obstructive sleep apnea syndrome

Sleep Apnea: Implications in Cardiovascular and Cerebrovascular Disease

Volumn , Issue , 2016, Pages 110-122

  Garvey, John ^a   Ryan, Silke ^a   Taylor, Cormac T ^a   Mcnicholas, Walter T ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84898753813     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (99)

1. Trepels T, Zeiher AM, Fichtlscherer S. The endothelium and inflammation. Endothelium 2006; 13(6):423-429.
2. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001; 12(4):383-389.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340(2):115-126.
4. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101 (16):1899-1906.
5. Li M, Georgakopoulos D, Lu G, et al. p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation 2005; 111(19):2494-2502.
6. Hickey MJ, Kubes P. Role of nitric oxide in regulation of leucocyte-endothelial cell interactions. Exp Physiol 1997; 82(2):339-348.
7. Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol 2006; (176 pt 1):213-254.
8. Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis 1995; 38(2):105-128.
9. Korhonen R, Lahti A, Kankaanranta H, et al. Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy 2005; 4(4):471-479.
10. Grisham MB, Granger DN, Lefer DJ. Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. Free Radic Biol Med 1998; 25(4-5):404-433.
11. Pellegrino D, Shiva S, Angelone T, et al. Nitrite exerts potent negative inotropy in the isolated heart via eNOS-independent nitric oxide generation and cGMP-PKG pathway activation. Biochim Biophys Acta 2009; 1787(7):818-827.
12. Erusalimsky JD, Moncada S. Nitric oxide and mitochondrial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27(12):2524-2531.
13. Schulz R, Schmidt D, Blum A, et al. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax 2000; 55(12):1046-1051.
14. Ip MS, Lam B, Chan LY, et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med 2000; 162(6):2166-2171.
15. Dean RT, Wilcox I. Possible atherogenic effects of hypoxia during obstructive sleep apnea. Sleep 1993; 16(8 suppl):S15-S21; discussion S-2.
16. Lavie L. Obstructive sleep apnoea syndrome-an oxidative stress disorder. Sleep Med Rev 2003; 7(1):35-51.
17. Svatikova A, Wolk R, Wang HH, et al. Circulating free nitrotyrosine in obstructive sleep apnea. Am J Physiol Regul Integr Comp Physiol 2004; 287(2):R284-R287.
18. Jelic S, Padeletti M, Kawut SM, et al. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 2008; 117(17):2270-2278.
19. Kraiczi H, Hedner J, Peker Y, et al. Increased vasoconstrictor sensitivity in obstructive sleep apnea. J Appl Physiol 2000; 89(2):493-498.
20. Kato M, Roberts-Thomson P, Phillips BG, et al. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 2000; 102(21):2607-2610.
21. Møller DS, Lind P, Strunge B, et al. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 2003; 16(4):274-280.
22. Grimpen F, Kanne P, Schulz E, et al. Endothelin-1 plasma levels are not elevated in patients with obstructive sleep apnoea. Eur Respir J 2000; 15(2):320-325.
23. Phillips BG, Narkiewicz K, Pesek CA, et al. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 1999; 17(1):61-66.
24. Saarelainen S, Seppala E, Laasonen K, et al. Circulating endothelin-1 in obstructive sleep apnea. Endothelium 1997; 5(2):115-118.
25. Jordan W, Reinbacher A, Cohrs S, et al. Obstructive sleep apnea: plasma endothelin-1 precursor but not endothelin-1 levels are elevated and decline with nasal continuous positive airway pressure. Peptides 2005; 26(9):1654-1660.
26. El Solh AA, Akinnusi ME, Baddoura FH, et al. Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med 2007; 175(11):1186-1191.
27. Martin K, Stanchina M, Kouttab N, et al. Circulating endothelial cells and endothelial progenitor cells in obstructive sleep apnea. Lung 2008; 186(3):145-150.
28. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39(1):44-84.
29. Lefer DJ, Granger DN. Oxidative stress and cardiac disease. Am J Med 2000; 109(4):315-323.
30. Molavi B, Mehta JL. Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. Curr Opin Cardiol 2004; 19(5):488-493.
31. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002; 165(7):934-939.
32. Schulz R, Mahmoudi S, Hattar K, et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000; 162(2 pt 1):566-570.
33. Barcelo A, Miralles C, Barbe F, et al. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 2000; 16(4):644-647.
34. Barcelo A, Barbe F, de la Pena M, et al. Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J 2006; 27(4):756-760.
35. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004; 27(1):123-128.
36. Christou K, Moulas AN, Pastaka C, et al. Antioxidant capacity in obstructive sleep apnea patients. Sleep Med 2003; 4(3):225-228.
37. Svatikova A, Wolk R, Lerman LO, et al. Oxidative stress in obstructive sleep apnoea. Eur Heart J 2005; 26(22):2435-2439.
38. Wali SO, Bahammam AS, Massaeli H, et al. Susceptibility of LDL to oxidative stress in obstructive sleep apnea. Sleep 1998; 21(3):290-296.
39. Ozturk L, Mansour B, Yuksel M, et al. Lipid peroxidation and osmotic fragility of red blood cells in sleep-apnea patients. Clin Chim Acta 2003; 332(1-2):83-88.
40. Montgomery-Downs HE, Krishna J, Roberts LJ II, et al. Urinary F2-isoprostane metabolite levels in children with sleep-disordered breathing. Sleep Breath 2006; 10(4):211-215.
41. Yamauchi M, Nakano H, Maekawa J, et al. Oxidative stress in obstructive sleep apnea. Chest 2005; 127(5):1674-1679.
42. Grossman E. Does increased oxidative stress cause hypertension? Diabetes Care 2008; 31 (suppl 2):S185-S189.
43. Juranek I, Bezek S. Controversy of free radical hypothesis: reactive oxygen species-cause or consequence of tissue injury? Gen Physiol Biophys 2005; 24(3):263-278.
44. Khalid MA, Ashraf M. Direct detection of endogenous hydroxyl radical production in cultured adult cardiomyocytes during anoxia and reoxygenation. Is the hydroxyl radical really the most damaging radical species? Circ Res 1993; 72(4):725-736.
45. Villa P, Carugo C, Guaitani A. No evidence of intracellular oxidative stress during ischemiareperfusion damage in rat liver in vivo. Toxicol Lett 1992; 61(2-3):283-290.
46. D'Autreaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 2007; 8(10):813-824.
47. Ravati A, Ahlemeyer B, Becker A, et al. Preconditioning-induced neuroprotection is mediated by reactive oxygen species and activation of the transcription factor nuclear factorkappaB. J Neurochem 2001; 78(4):909-919.
48. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. Jama 2007; 297(8):842-857.
49. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112(17):2660-2667.
50. Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006; 174(7): 824-830.
51. Ciftci TU, Kokturk O, Bukan N, et al. The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine 2004; 28(2):87-91.
52. Dyugovskaya L, Lavie P, Lavie L. Phenotypic and functional characterization of blood gammadelta T cells in sleep apnea. Am J Respir Crit Care Med 2003; 168(2):242-249.
53. Minoguchi K, Tazaki T, Yokoe T, et al. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. Chest 2004; 126(5):1473-1479.
54. Aukrust P, Yndestad A, Smith C, et al. Chemokines in cardiovascular risk prediction. Thromb Haemost 2007; 97(5):748-754.
55. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398(6729):718-723.
56. Ohga E, Tomita T, Wada H, et al. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 2003; 94(1):179-184.
57. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997; 82(5):1313-1316.
58. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107(8):1129-1134.
59. Mehra R, Storfer-Isser A, Kirchner HL, et al. Soluble interleukin 6 receptor: a novel marker of moderate to severe sleep-related breathing disorder. Arch Intern Med 2006; 166(16):1725-1731.
60. Ueda K, Takahashi M, Ozawa K, et al. Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction. Am Heart J 1999; 138(5 pt 1):908-915.
61. Ohga E, Nagase T, Tomita T, et al. Increased levels of circulating ICAM-1, VCAM-1, and Lselectin in obstructive sleep apnea syndrome. J Appl Physiol 1999; 87(1):10-14.
62. Ursavas A, Karadag M, Rodoplu E, et al. Circulating ICAM-1 and VCAM-1 levels in patients with obstructive sleep apnea syndrome. Respiration 2007;74(5):525-532.
63. Zamarron-Sanz C, Ricoy-Galbaldon J, Gude-Sampedro F, et al. Plasma levels of vascular endothelial markers in obstructive sleep apnea. Arch Med Res 2006; 37(4):552-555.
64. El-Solh AA, Mador MJ, Sikka P, et al. Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest 2002; 121(5):1541-1547.
65. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98(8):731-733.
66. Koenig W, Sund M, Frohlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men:results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99(2):237-242.
67. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349(9050):462-466.
68. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000; 35(6):1535-1542.
69. Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 2005; 165(18):2063-2068.
70. Khera A, de Lemos JA, Peshock RM, et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 2006; 113(1):38-43.
71. Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality:the Cardiovascular Health Study. Circulation 2007; 116(1):32-38.
72. Yao M, Tachibana N, Okura M, et al. The relationship between sleep-disordered breathing and high-sensitivity C-reactive protein in Japanese men. Sleep 2006; 29(5):661-665.
73. Taheri S, Austin D, Lin L, et al. Correlates of serum C-reactive protein (CRP)-no association with sleep duration or sleep disordered breathing. Sleep 2007; 30(8):991-996.
74. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105(21):2462-2464.
75. Kokturk O, Ciftci TU, Mollarecep E, et al. Elevated C-reactive protein levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome. Int Heart J 2005; 46 (5):801-809.
76. Can M, Acikgoz S, Mungan G, et al. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 2006; 129(2):233-237.
77. Barcelo A, Barbe F, Llompart E, et al. Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med 2004; 117(2):118-121.
78. Guilleminault C, Kirisoglu C, Ohayon MM. C-reactive protein and sleep-disordered breathing. Sleep 2004; 27(8):1507-1511.
79. Ryan S, Nolan GM, Hannigan E, et al. Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity. Thorax 2007; 62(6):509-514.
80. Akashiba T, Akahoshi T, Kawahara S, et al. Effects of long-term nasal continuous positive airway pressure on C-reactive protein in patients with obstructive sleep apnea syndrome. Intern Med 2005; 44(8):899-900.
81. Steiropoulos P, Tsara V, Nena E, et al. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest 2007; 132(3):843-851.
82. Libby P. Inflammation in atherosclerosis. Nature 2002; 420(6917):868-874.
83. Lusis AJ. Atherosclerosis. Nature 2000; 407(6801):233-241.
84. Nacher M, Serrano-Mollar A, Farre R, et al. Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. Respir Physiol Neurobiol 2007; 155(1):93-96.
85. Lattimore JD, Wilcox I, Nakhla S, et al. Repetitive hypoxia increases lipid loading in human macrophages-a potentially atherogenic effect. Atherosclerosis 2005; 179(2):255-259.
86. Dyugovskaya L, Lavie P, Hirsh M, et al. Activated CD8+ T-lymphocytes in obstructive sleep apnoea. Eur Respir J 2005; 25(5):820-828.
87. Dyugovskaya L, Polyakov A, Lavie P, et al. Delayed neutrophil apoptosis in sleep apnea patients. Am J Respir Crit Care Med 2008; 177(5):544-554.
88. Greenberg H, Ye X, Wilson D, et al. Chronic intermittent hypoxia activates nuclear factorkappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 2006; 343(2):591-596.
89. Yamauchi M, Tamaki S, Tomoda K, et al. Evidence for activation of nuclear factor kappaB in obstructive sleep apnea. Sleep Breath 2006; 10(4):189-193.
90. Ryan S, McNicholas WT, Taylor CT. A critical role for p38 map kinase in NF-kappaB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 2007; 355(3):728-733.
91. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999; 1(2):94-97.
92. Cook SA, Sugden PH, Clerk A. Activation of c-Jun N-terminal kinases and p38-mitogenactivated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol 1999; 31(8):1429-1434.
93. Behr TM, Nerurkar SS, Nelson AH, et al. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 2001; 104(11):1292-1298.
94. Cain BS, Meldrum DR, Meng X, et al. p38 MAPK inhibition decreases TNF-alpha production and enhances postischemic human myocardial function. J Surg Res 1999; 83(1):7-12.
95. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4(5):E131-E136.
96. Yuan G, Nanduri J, Bhasker CR, et al. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 2005; 280(6):4321-4328.
97. Greenberg HE, Sica AL, Scharf SM, et al. Expression of c-fos in the rat brainstem after chronic intermittent hypoxia. Brain Res 1999; 816(2):638-645.
98. Goldbart A, Row BW, Kheirandish L, et al. Intermittent hypoxic exposure during light phase induces changes in cAMP response element binding protein activity in the rat CA1 hippocampal region: water maze performance correlates. Neuroscience 2003;122(3):585-590.
99. Hayakawa M, Miyashita H, Sakamoto I, et al. Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J 2003; 22(13):3356-3366.